Showing 1 - 11 results of 11 for search 'Xiao-Zhong Chen', query time: 0.04s Refine Results
  1. 1
    ABO blood group is a predictor of survival in patients with laryngeal cancer

    ABO blood group is a predictor of survival in patients with laryngeal cancer by Ting Jin, Pei-Jing Li, Xiao-Zhong Chen, Wei-Han Hu

    Published 2016-10-01
    Get full text
    Article
  2. 2
    Endostar Combined with Gemcitabine and Cisplatin Chemotherapy for Patients with Metastatic Nasopharyngeal Carcinoma: an Update

    Endostar Combined with Gemcitabine and Cisplatin Chemotherapy for Patients with Metastatic Nasopharyngeal Carcinoma: an Update by Ting Jin, Feng Jiang, Qi-Feng Jin, Yong-Feng Piao, Xiao-Zhong Chen

    Published 2018-04-01
    Get full text
    Article
  3. 3
    Metabolites Produced by the Endophytic Fungus Aspergillus fumigatus from the Stem of Erythrophloeum fordii Oliv.

    Metabolites Produced by the Endophytic Fungus Aspergillus fumigatus from the Stem of Erythrophloeum fordii Oliv. by Yu-Sheng Shi, Yan Zhang, Xiao-Zhong Chen, Ning Zhang, Yun-Bao Liu

    Published 2015-06-01
    Get full text
    Article
  4. 4
    Anti-PD1 checkpoint inhibitor with or without chemotherapy for patients with recurrent and metastatic nasopharyngeal carcinoma

    Anti-PD1 checkpoint inhibitor with or without chemotherapy for patients with recurrent and metastatic nasopharyngeal carcinoma by Ting Jin, Qun Zhang, Qi-Feng Jin, Yong-Hong Hua, Xiao-Zhong Chen

    Published 2021-02-01
    Get full text
    Article
  5. 5
    Oral Mucosa Dose Parameters Predicting Grade ≥3 Acute Toxicity in Locally Advanced Nasopharyngeal Carcinoma Patients Treated With Concurrent Intensity-Modulated Radiation Therapy and Chemotherapy: An Independent Validation Study Comparing Oral Cavity versus Mucosal Surface Contouring Techniques

    Oral Mucosa Dose Parameters Predicting Grade ≥3 Acute Toxicity in Locally Advanced Nasopharyngeal Carcinoma Patients Treated With Concurrent Intensity-Modulated Radiation Therapy a... by Kaixin Li, Ling Yang, Qiang-ying Hu, Xiao-zhong Chen, Ming Chen, Yuanyuan Chen

    Published 2017-10-01
    Get full text
    Article
  6. 6
    Radiation dose escalation for locally advanced nasopharyngeal carcinoma patients with local and/or regional residual lesions after standard chemoradiotherapy: a non-randomized, observational study

    Radiation dose escalation for locally advanced nasopharyngeal carcinoma patients with local and/or regional residual lesions after standard chemoradiotherapy: a non-randomized, obs... by Ting Jin, Nan-Fang Liu, Qi-Feng Jin, Yong-Hong Hua, Xiao-Zhong Chen

    Published 2022-11-01
    Get full text
    Article
  7. 7
    Concurrent Chemoradiotherapy With or Without Induction Chemotherapy for Patients with Stage II Nasopharyngeal Carcinoma: An Update

    Concurrent Chemoradiotherapy With or Without Induction Chemotherapy for Patients with Stage II Nasopharyngeal Carcinoma: An Update by Ting Jin, Qun Zhang, Dong-Hua Luo, Feng Jiang, Qi-Feng Jin, Yuan-Yuan Chen, Xiao-Zhong Chen, Wei-Min Mao

    Published 2020-01-01
    Get full text
    Article
  8. 8
    Cisplatin and Fluorouracil Induction Chemotherapy With or Without Docetaxel in Locoregionally Advanced Nasopharyngeal Carcinoma

    Cisplatin and Fluorouracil Induction Chemotherapy With or Without Docetaxel in Locoregionally Advanced Nasopharyngeal Carcinoma by Ting Jin, Wei-feng Qin, Feng Jiang, Qi-feng Jin, Qi-chun Wei, Yong-shi Jia, Xiao-nan Sun, Wen-feng Li, Xiao-zhong Chen

    Published 2019-04-01
    Get full text
    Article
  9. 9
    Predictive Model and Precaution for Oral Mucositis During Chemo-Radiotherapy in Nasopharyngeal Carcinoma Patients

    Predictive Model and Precaution for Oral Mucositis During Chemo-Radiotherapy in Nasopharyngeal Carcinoma Patients by Pei-Jing Li, Kai-Xin Li, Ting Jin, Hua-Ming Lin, Jia-Ben Fang, Shuang-Yan Yang, Wei Shen, Jia Chen, Jiang Zhang, Xiao-Zhong Chen, Ming Chen, Yuan-Yuan Chen

    Published 2020-11-01
    Get full text
    Article
  10. 10
    Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma treated with PD-1 blockade: data from a multicohort phase 2 studyResearch in context

    Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma treated with PD-1 blockade: data from a multicohort phase 2 studyResearch in context by Xi Ding, Yi-Jun Hua, Xiong Zou, Xiao-Zhong Chen, Xi-Mei Zhang, Bei Xu, Yan-Feng Ouyang, Zi-Wei Tu, Hui-Feng Li, Chong-Yang Duan, Wei-Jing Zhang, Rui You, You-Ping Liu, Yong-Long Liu, Qi Yang, Pei-Yu Huang, Shu-Ni Wang, Jia Fan, Ming-Yuan Chen

    Published 2023-07-01
    Get full text
    Article
  11. 11
    The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma

    The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma by Ling‐Long Tang, Yu‐Pei Chen, Chuan‐Ben Chen, Ming‐Yuan Chen, Nian‐Yong Chen, Xiao‐Zhong Chen, Xiao‐Jing Du, Wen‐Feng Fang, Mei Feng, Jin Gao, Fei Han, Xia He, Chao‐Su Hu, De‐sheng Hu, Guang‐Yuan Hu, Hao Jiang, Wei Jiang, Feng Jin, Jin‐Yi Lang, Jin‐Gao Li, Shao‐Jun Lin, Xu Liu, Qiu‐Fang Liu, Lin Ma, Hai‐Qiang Mai, Ji‐Yong Qin, Liang‐Fang Shen, Ying Sun, Pei‐Guo Wang, Ren‐Sheng Wang, Ruo‐Zheng Wang, Xiao‐Shen Wang, Ying Wang, Hui Wu, Yun‐Fei Xia, Shao‐Wen Xiao, Kun‐Yu Yang, Jun‐Lin Yi, Xiao‐Dong Zhu, Jun Ma

    Published 2021-11-01
    Get full text
    Article

Search Tools: